Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Deals

Novo Nordisk Partners with GE HealthCare to Develop Non-Invasive Treatment for Chronic Diseases

Fineline Cube Oct 20, 2023

Metabolism expert Novo Nordisk (NYSE: NVO) has announced a partnership with medical technology firm GE...

Company Deals

MSD Collaborates with Daiichi Sankyo on Development of Innovative ADC Candidates

Fineline Cube Oct 20, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic collaboration agreement with Japan-based...

Company

HuidaGene Receives FDA Rare Pediatric Disease Designation for MECP2 Syndrome Therapy

Fineline Cube Oct 19, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced that it has received Rare Pediatric Disease...

Company

Kyowa Hakko Kirin Doubles Manufacturing Capacity with Shanghai Plant Expansion

Fineline Cube Oct 19, 2023

Japan-based biopharmaceutical company Kyowa Hakko Kirin has announced the successful completion and operational status of...

Company Deals

Sansure Biotech Partners with Shaanxi Lifegen to Boost Molecular Diagnostics

Fineline Cube Oct 19, 2023

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has formed a strategic partnership with...

Company Deals

Alebund Pharmaceuticals Secures Exclusive Rights to Roche’s Mircera in China

Fineline Cube Oct 19, 2023

Shanghai-based Alebund Pharmaceuticals has entered into a commercialization agreement with Swiss pharmaceutical giant Roche (SWX:...

Company Drug

AstraZeneca’s Soliris Gains Approval in China for NMOSD Treatment

Fineline Cube Oct 19, 2023

UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) has announced that its rare disease drug...

Legal / IP

CNIPA Upholds Alnylam’s PCSK9-Targeted siRNA Patent Against Junshi Biosciences Challenge

Fineline Cube Oct 19, 2023

The China National Intellectual Property Administration (CNIPA) has rejected another challenge from Junshi Biosciences (SHA:...

Company Drug

Qilu Pharmaceutical Presents Promising Data for QL1706 and QL1209 at ESMO 2023

Fineline Cube Oct 19, 2023

China-based Qilu Pharmaceutical has announced the presentation of clinical data for two of its pipeline...

Company Drug

Guangdong Zhongsheng Launches AI Q&A Bot for Leritrelvir Drug Support

Fineline Cube Oct 19, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the innovative launch of a...

Company R&D

WuXi XDC Partners with Hong Kong Science Park to Boost CRDMO Value Chain

Fineline Cube Oct 19, 2023

WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary...

Company Deals

AlphaGen Therapeutics Secures Seed Funding for Pb-212 Radioligand Therapy Development

Fineline Cube Oct 19, 2023

AlphaGen Therapeutics Ltd, a Shanghai-based developer specializing in radioligand therapy (RLT), has reportedly secured “tens...

Company Drug

Boehringer Ingelheim’s Vitiligo Drug EI-001 Approved for Clinical Trials by NMPA

Fineline Cube Oct 19, 2023

Germany’s Boehringer Ingelheim (BI) has announced that the National Medical Products Administration (NMPA) has approved...

Company Deals

Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services

Fineline Cube Oct 19, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759)...

Company Drug

Haisco Pharmaceutical’s HSK21542 Accepted for NMPA Review in Postoperative Pain Management

Fineline Cube Oct 19, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...

Policy / Regulatory

NMPA Issues Guidelines for Temporary Import of Urgently Needed Medical Devices

Fineline Cube Oct 19, 2023

The National Medical Products Administration (NMPA) has released new “Management Requirements for Temporary Import and...

Company

Abbott Reports 8.7% Drop in Q3 2023 Global Sales, Hit by Lower SARS-CoV-2 Test Demand

Fineline Cube Oct 19, 2023

Abbott (NYSE: ABT) published its Q3 2023 financial results this week, reporting a 8.7% year-on-year...

Company Drug

Roche’s Alecensa Shows Unprecedented 76% Improvement in Disease-Free Survival in NSCLC Trial

Fineline Cube Oct 19, 2023

Roche (SWX: ROG) subsidiary Genentech has revealed preliminary but promising results from a Phase III...

Company Deals

Eli Lilly Acquires Mablink Bioscience to Expand Next-Gen ADC Portfolio

Fineline Cube Oct 19, 2023

US pharmaceutical company Eli Lilly (NYSE: LLY) has signed an agreement to acquire France-based Mablink...

Company Deals

Belief BioMed Partners with Takeda for BBM-H901 Commercialization in Asia

Fineline Cube Oct 18, 2023

Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced a strategic partnership with Japan’s...

Posts pagination

1 … 510 511 512 … 718

Recent updates

  • Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers
  • METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform
  • Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection
  • CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours
  • HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Company Drug

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.